Inhibitory effect of docosahexaenoic acid (DHA) on the intestinal metabolism of midazolam: In vitro and in vivo studies in rats

International Journal of Pharmaceutics

Volumn 351, Issue 1-2, 2008, Pages 133-143

  Hirunpanich, V ^b   Murakoso, K ^a   Sato, H ^a  

^a SHOWA UNIVERSITY   (Japan)

^b MAHASARAKHAM UNIVERSITY   (Thailand)

Author keywords

CYP3A; Docosahexeanoic acid (DHA); Midazolam; P glycoprotein (P gp); Perfused everted intestinal segment; Rhodamine 123

Indexed keywords

4 HYDROXYMIDAZOLAM; ALPHA HYDROXYMIDAZOLAM; CYTOCHROME P450 3A; DOCOSAHEXAENOIC ACID; DRUG METABOLITE; GLYCOPROTEIN P; MIDAZOLAM; RHODAMINE 123; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG METABOLISM; DRUG TRANSPORT; ENZYME ACTIVITY; INTESTINE; INTESTINE MUCOSA; LIVER CLEARANCE; MALE; MICROSOME; NONHUMAN; PRIORITY JOURNAL; RAT; SEROSA;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; CYTOCHROME P-450 CYP3A; DOCOSAHEXAENOIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; HALF-LIFE; INTESTINES; MALE; MICROSOMES; MIDAZOLAM; P-GLYCOPROTEIN; RATS; RATS, WISTAR; RHODAMINE 123; TISSUE DISTRIBUTION;

EID: 39049093665     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2007.09.037     Document Type: Article

References (37)

1. Achira M., Suzuki H., Ito K., and Sugiyama Y. Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P4503A4. AAPS Pharm. Sci. 1 (1999) E18
2. Arterburn L.M., Boswell K.D., Henwood S.M., and Kyle D.J. A developmental safety study in rats using DHA- and ARA-rich single-cell oils. Food Chem. Toxicol. 38 (2000) 763-771
3. Barthe L., Woodley J., and Houin G. Gastrointestinal absorption of drugs: methods and studies. Fundam. Clin. Pharmacol. 13 (1999) 154-168
4. Bays H. Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids. Am. J. Cardiol. 98 (2006) 71i-76i
5. Benet L.Z., Izumi T., Zhang Y., Silverman J.A., and Wacher V.J. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. J. Control. Release 62 (1999) 25-31
6. Benet L.Z., Cummins C.L., and Wu C.Y. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int. J. Pharm. 277 (2004) 3-9
7. Berggren S., Lennernas P., Ekelund M., Westrom B., Hoogstraate J., and Lennernas H. Regional transport and metabolism of ropivacaine and its CYP3A4 metabolite PPX in human intestine. J. Pharm. Pharmacol. 55 (2003) 963-972
8. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
9. Carrillo J.A., Ramos S.I., Agundez J.A., Martinez C., and Benitez J. Analysis of midazolam and metabolites in plasma by high-performance liquid chromatography: probe of CYP3A. Ther. Drug Monit. 20 (1998) 319-324
10. Cho C.W., Liu Y., Yan X., Henthorn T., and Ng K.Y. Carrier-mediated uptake of rhodamine 123: implications on its use for MDR research. Biochem. Biophys. Res. Commun. 279 (2000) 124-130
11. Cotreau M.M., von Moltke L.L., Harmatz J.S., and Greenblatt D.J. Molecular and pharmacokinetic evaluation of rat hepatic and gastrointestinal cytochrome p450 induction by tamoxifen. Pharmacology 63 (2001) 210-219
12. Food and Drug Administration, 2004. Omacor's approved label. Food and Drug Administration. Available at http://www.fda.gov/cder/foi/label/2004/21654lbl.pdf (accessed June 2006).
13. Fisher J.M., Wrighton S.A., Watkins P.B., Schmiedlin-Ren P., Calamia J.C., Shen D.D., Kunze K.L., and Thummel K.E. First-pass midazolam metabolism catalyzed by 1alpha, 25-dihydroxy vitamin D3-modified Caco-2 cell monolayers. J. Pharmacol. Exp. Ther. 289 (1999) 1134-1142
14. Gandia P., Lacombe O., Woodley J., and Houin G. The perfused everted intestinal segment of rat. 1st communication: absorption kinetics of markers of different permeation mechanisms. Arzneimittelforschung 54 (2004) 467-473
15. Goho C. Oral midazolam-grapefruit juice drug interaction. Pediatr. Dent. 23 (2001) 365-366
16. Hare J.T., and Elliott D.P. Grapefruit juice and potential drug interactions. Consult. Pharm. 18 (2003) 466-472
17. Higashikawa F., Murakami T., Kaneda T., Kato A., and Takano M. Dose-dependent intestinal and hepatic first-pass metabolism of midazolam, a cytochrome P450 3A substrate with differently modulated enzyme activity in rats. J. Pharm. Pharmacol. 51 (1999) 67-72
18. Hirunpanich V., Katagi J., Sethabouppha B., and Sato H. Demonstration of docosahexaenoic acid as a bioavailability enhancer for CYP3A substrates: in vitro and in vivo evidence using cyclosporin in rats. Drug Metab. Dispos. 34 (2005) 305-310
19. Hirunpanich V., and Sato H. Docosahexaenoic acid (DHA) inhibits saquinavir metabolism in-vitro and enhances its bioavailability in rats. J. Pharm. Pharmacol. 58 (2006) 651-658
20. Iida A., Tomita M., and Hayashi M. Regional difference in P-glycoprotein function in rat intestine. Drug Metab. Pharmacokinet. 20 (2005) 100-106
21. Johnson T.N., Rostami-Hodjegan A., Goddard J.M., Tanner M.S., and Tucker G.T. Contribution of midazolam and its 1-hydroxy metabolite to preoperative sedation in children: a pharmacokinetic-pharmacodynamic analysis. Br. J. Anaesth. 89 (2002) 428-437
22. Kim H., Yoon Y.J., Shon J.H., Cha I.J., Shin J.G., and Liu K.H. Inhibitory effects of fruit juices on CYP3A activity. Drug Metab. Dispos. 34 (2006) 521-523
23. Kim R.B., Wandel C., Leake B., Cvetkovic M., Fromm M.F., Dempsey P.J., Roden M.M., Belas F., Chaudhary A.K., Roden D.M., Wood A.J., and Wilkinson G.R. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm. Res. 16 (1999) 408-414
24. Kivisto K.T., Niemi M., and Fromm M F. Functional interaction of intestinal CYP3A4 and P-glycoprotein. Fundam. Clin. Pharmacol. 18 (2004) 621-626
25. Kotegawa T., Laurijssens B.E., Von Moltke L.L., Cotreau M.M., Perloff M.D., Venkatakrishnan K., Warrington J.S., Granda B.W., Harmatz J.S., and Greenblatt D.J. In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat. J. Pharmacol. Exp. Ther. 302 (2002) 1228-1237
26. Lee J.S., Paull K., Alvarez M., Hose C., Monks A., Grever M., Fojo A.T., and Bates S.E. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol. Pharmacol. 46 (1994) 627-638
27. Obach R.S., Walsky R.L., Venkatakrishnan K., Gaman E.A., Houston J.B., and Tremaine L.M. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J. Pharmacol. Exp. Ther. 316 (2006) 336-348
28. Paine M.F., Shen D.D., Kunze K.L., Perkins J.D., Marsh C.L., McVicar J.P., Barr D.M., Gillies B.S., and Thummel K.E. First-pass metabolism of midazolam by the human intestine. Clin. Pharmacol. Ther. 60 (1996) 14-24
29. Polli J.W., Wring S.A., Humphreys J.E., Huang L., Morgan J.B., Webster L.O., and Serabjit-Singh C.S. Rational use of in vitro P-glycoprotein assays in drug discovery. J. Pharmacol. Exp. Ther. 299 (2001) 620-628
30. Quinney, S.K., Haehner, B.D., Rhoades, M.B., Lin, Z., Gorski, J.C., Hall, S.D., 2007. Interaction between midazolam and clarithromycin in the elderly. Br. J. Clin. Pharmacol., in press.
31. Sawada Y., Takedomi S., Matsuo H., Yamano K., Iga T., and Ohtani H. Effects of single and repeated treatment with itraconazole on the pharmacokinetics of midazolam in rats. Drug Metab. Pharmacokinet. 17 (2002) 275-283
32. 13C-labeled docosahexaenoic acid and docosapentaenoic acid in Red Sea Bream Chrysophrys major. J. World Aqua. Soc. 33 (2002) 118-126
33. Thummel K.E., O'Shea D., Paine M.F., Shen D.D., Kunze K.L., Perkins J.D., and Wilkinson G.R. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin. Pharmacol. Ther. 59 (1996) 491-502
34. Tolle-Sander S., Rautio J., Wring S., Polli J.W., and Polli J.E. Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate. Pharm. Res. 20 (2003) 757-764
35. Yao H.T., Chang Y.W., Lan S.J., Chen C.T., Hsu J.T., and Yeh T.K. The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes. Life Sci. 79 (2006) 2432-2440
36. Yumoto R., Murakami T., Nakamoto Y., Hasegawa R., Nagai J., and Takano M. Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds. J. Pharmacol. Exp. Ther. 289 (1999) 149-155
37. Zhang Q.Y., Dunbar D., Ostrowska A., Zeisloft S., Yang J., and Kaminsky L.S. Characterization of human small intestinal cytochromes P-450. Drug Metab. Dispos. 27 (1999) 804-809